Neurological drugs are hard. Two companies bet ‘chemogenetics’ can help

Neurological drugs are hard. Two companies bet ‘chemogenetics’ can help

STAT Plus: Two companies bet on ‘chemogenetics’ to sidestep challenges with neurological drug development 

By KATE SHERIDAN

ADOBE

Redpin and CODA are taking existing compounds, tailoring receptors to match, and delivering the genetic code for the bespoke receptors via gene therapy.

READ MORE